An unlicensed Chinese inventor is collaborating with a former pharmaceutical executive to introduce high-concentration chlorine dioxide injections—essentially industrial bleach—into the United States as a fringe cancer treatment, capitalizing on a shifting political landscape and the “Make America Healthy Again” movement. Despite reports of agonizing side effects and potential disease acceleration, inventor Liu and his partner, Scott Hagerman, are actively lobbying to bypass traditional FDA pathways to bring this unproven protocol to American clinics by 2026.
From Pseudoscience to Intratumoral Injections
For decades, chlorine dioxide has been marketed under the guise of “Miracle Mineral Solution” (MMS), a toxic substance falsely claimed to cure everything from HIV to autism. While previous iterations involved drinking diluted solutions, Liu’s method escalates the risk significantly. He advocates for the direct injection of 20,000 ppm chlorine dioxide—a concentration far higher than previous “treatments”—directly into cancerous tumors.
Liu, who operates out of a rented apartment in Beijing, admits to the volatile nature of his work. He recently detailed a “violent explosion” in his home lab that caused ocular damage and respiratory burns, occurring while his three-year-old daughter was nearby. Despite no formal medical training, Liu claims to have treated 20 patients across China and Germany, though his “evidence” consists largely of unvetted pitch decks and WhatsApp screenshots rather than peer-reviewed clinical data.
Exploiting the Political Shift in US Health Policy
The push to legalize these injections in the U.S. relies heavily on the anticipated influence of Robert F. Kennedy Jr. and a broader movement toward alternative medicine. Liu and Hagerman believe that the recent removal of a chlorine dioxide warning from the FDA website—which the agency describes as routine archiving—signals a “door opening” for unproven therapies.
“Without the FDA’s heavy-handed warnings, it’s likely my therapy would have been accepted for trials years earlier,” Liu told reporters. He is currently targeting “liberty-leaning states” to lobby for experimental use, incorrectly citing the “Right to Try” Act and the Declaration of Helsinki as legal justifications for marketing his protocol without federal oversight.
Patient Reports: Agony and Disease Progression
While Liu promotes his injections as a breakthrough, patient testimonies paint a harrowing picture of the reality on the ground. One Chinese national living in the UK, who self-administered the injections after contacting Liu, reported experiencing “severe pain” unlike anything she had ever felt. More disturbingly, she noted that while the tumor initially shrank, it subsequently grew faster and spread to her skin.
“I suspect it is because the chlorine dioxide has broken the vein and the cancer cells go to the skin area,” she stated. Liu dismissed these concerns, attributing the failure to the patient not completing his prescribed course of four injections. Other patients reported similar complications, including difficulty urinating and extreme swelling following injections for vaginal cancer.
The German Connection and the “Illegal Treatment” Label
Currently, the treatment is allegedly offered at the CMC Rheinfelden clinic on the German-Swiss border. However, the facility’s operations appear shrouded in secrecy. Internal communications revealed that the clinic avoids listing the procedure on invoices or its website because it is “not a legal treatment.”
Despite these red flags, Liu claims to have a waitlist of over 100 U.S. patients desperate for alternatives. Some American facilities, such as the Williams Cancer Institute in Beverly Hills, have reportedly expressed interest in Liu’s protocol, further blurring the lines between legitimate medical research and dangerous experimentation.
The Pharmaceutical Insider Turning Against the System
Liu’s primary American ally is Scott Hagerman, a former Pfizer employee and pharmaceutical executive with 30 years of industry experience. Hagerman, who now refers to the pharmaceutical industry as a “corrupt entity” and a “drugs cartel,” views Liu’s lack of medical credentials as an asset.
“I would welcome the fact that he’s not a doctor… because he’s not clouded, jaded, and biased,” Hagerman said. He expressed 100% certainty that investors will fund the development of these injections, aiming for a legal U.S. presence by the end of 2025. However, oncology experts like Alex Morozov warn that treating patients outside of controlled clinical trials is ethically and medically indefensible, regardless of the political climate.
